The Pharmacodynamics, Pharmacokinetics, and Safety of Dapagliflozin in Type 2 Diabetic Subjects With Mild, Moderate, and Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Mar 2009 Results presented at ASCPT
- 14 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from active, no longer recruiting to completed.